Akoya Biosciences announced that the company’s PhenoCycler Fusion and PhenoImager HT spatial proteomics platforms will be used to analyze tissue samples as part of the MANIFEST program. This multimillion-dollar initiative, funded by the UK Office of Life Sciences and the Medical Research Council, aims to advance cancer immunotherapy research through deep multi-omic profiling. The MANIFEST consortium brings together leading cancer researchers, academic institutions, NHS trusts, and industry partners, to study why certain cancer patients respond to immunotherapy while others do not. Akoya’s spatial biology platforms will play a pivotal role in profiling immune cell interactions within the tumor microenvironment, offering critical insights into biomarkers that may predict treatment outcomes and potential side effects.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.